Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Houten

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Pharmacoeconomics - Open|April 21, 2023
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology AppraisalRachel Houten, Nigel Fleeman, James Mahon, et al.
Health Technology Assessment (Winchester, England)|January 15, 2020
Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluationNigel Fleeman, Rachel Houten, Adrian Bagust, et al.
Pharmacoeconomics - Open|November 5, 2024
Digital Versus Paper-Based Consent from the UK NHS Perspective: A Micro-costing AnalysisRachel Houten, Mohammad Iqbal Hussain, Antony P Martin, et al.
Health Technology Assessment (Winchester, England)|October 15, 2023
Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non-alcoholic fatty liver disease: systematic review and economic evaluationRebecca Bresnahan, Rui Duarte, James Mahon, et al.
Pharmacoeconomics - Open|May 17, 2023
Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology AppraisalRebecca Bresnahan, Rachel Houten, Janette Greenhalgh, et al.
Frontiers in Pain Research (Lausanne, Switzerland)|September 23, 2022
Screening trials of spinal cord stimulation for neuropathic pain in England-A budget impact analysisRui V Duarte, Rachel Houten, Sarah Nevitt, et al.
Health Technology Assessment (Winchester, England)|September 10, 2024
Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysisNigel Fleeman, Rachel Houten, Sarah Nevitt, et al.
Neurosurgery|October 13, 2022
Does a Screening Trial for Spinal Cord Stimulation in Patients With Chronic Pain of Neuropathic Origin Have Clinical Utility (TRIAL-STIM)? 36-Month Results From a Randomized Controlled TrialSam Eldabe, Sarah Nevitt, Sara Griffiths, et al.
Pain|July 4, 2020
Does a screening trial for spinal cord stimulation in patients with chronic pain of neuropathic origin have clinical utility and cost-effectiveness (TRIAL-STIM)? A randomised controlled trialSam Eldabe, Rui V Duarte, Ashish Gulve, et al.
Neuromodulation : Journal of the International Neuromodulation Society|December 1, 2020
To Trial or Not to Trial Before Spinal Cord Stimulation for Chronic Neuropathic Pain: The Patients' View From the TRIAL-STIM Randomized Controlled TrialRaymond Chadwick, Rebekah McNaughton, Sam Eldabe, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Pharmacoeconomics - Open|April 21, 2023
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology AppraisalRachel Houten, Nigel Fleeman, James Mahon, et al.
Health Technology Assessment (Winchester, England)|January 15, 2020
Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluationNigel Fleeman, Rachel Houten, Adrian Bagust, et al.
Pharmacoeconomics - Open|November 5, 2024
Digital Versus Paper-Based Consent from the UK NHS Perspective: A Micro-costing AnalysisRachel Houten, Mohammad Iqbal Hussain, Antony P Martin, et al.
Health Technology Assessment (Winchester, England)|October 15, 2023
Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non-alcoholic fatty liver disease: systematic review and economic evaluationRebecca Bresnahan, Rui Duarte, James Mahon, et al.
Pharmacoeconomics - Open|May 17, 2023
Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology AppraisalRebecca Bresnahan, Rachel Houten, Janette Greenhalgh, et al.
Frontiers in Pain Research (Lausanne, Switzerland)|September 23, 2022
Screening trials of spinal cord stimulation for neuropathic pain in England-A budget impact analysisRui V Duarte, Rachel Houten, Sarah Nevitt, et al.
Health Technology Assessment (Winchester, England)|September 10, 2024
Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysisNigel Fleeman, Rachel Houten, Sarah Nevitt, et al.
Neurosurgery|October 13, 2022
Does a Screening Trial for Spinal Cord Stimulation in Patients With Chronic Pain of Neuropathic Origin Have Clinical Utility (TRIAL-STIM)? 36-Month Results From a Randomized Controlled TrialSam Eldabe, Sarah Nevitt, Sara Griffiths, et al.
Pain|July 4, 2020
Does a screening trial for spinal cord stimulation in patients with chronic pain of neuropathic origin have clinical utility and cost-effectiveness (TRIAL-STIM)? A randomised controlled trialSam Eldabe, Rui V Duarte, Ashish Gulve, et al.
Neuromodulation : Journal of the International Neuromodulation Society|December 1, 2020
To Trial or Not to Trial Before Spinal Cord Stimulation for Chronic Neuropathic Pain: The Patients' View From the TRIAL-STIM Randomized Controlled TrialRaymond Chadwick, Rebekah McNaughton, Sam Eldabe, et al.
Pageof 2